Current Clinical Trials

The clinical trials listed below are currently recruiting. Trials are held at centres throughout Australia.Please select the highlighted links to view additional information about the trial and the relevant contact details.

GSK Medicines Research Unit (Prince of Wales Hospital, Sydney)

Healthy Volunteers

S1P1 Agonist

Study Name: P1A114070 - A Single-blind, placebo-controlled, two part study to assess the safety, tolerability, pharmakokinetics and pharmacodynamics of single ascending doses of GSK2018682 (S1P1 agonist) in healthy volunteers.

Criteria: Age 18-55, non-smoker, not taking any regular medications. If female then must be surgically sterile or post-menopausal.

CCX114472 (Japanese Volunteers) 「治験」ってご存知ですか。

Study Name: CCX114472 - A placebo controlled, Four-Period Crossover, Single Ascending Oral Dose Escalation Study to assess the safety, Tolerability and Pharmakokinetics of the CCR9 Receptor Antagonist GSK1605786 (CCX282) in Japanese Health Male Subjects.

Criteria: 本人、父母二人、祖父母四人の全員が日本生まれ 4 grandparents, both parents & yourself have been born in Japan, ２０〜５５歳 , 20 - 55 years of age, 健康 Healthy

たばこをやめて６ヶ月以上 Ceased smoking at least 6 months ago,

日本語で会話、読み書きができる Communicate, write/read in Japanese,

オーストラリア在住十年以内 Residing outside of Japan for 10 years or less.

任意参加ですから、途中で嫌になればいつでもやめることができます。GSKの規則や条件を守り、最後までご協力下さった方には謝礼金を差し上げます。.
関心のある方は日本語でも英語でも結構ですから、下記に名前と電話番号とメールアドレスをお知らせ下さい。折り返し日本人スタッフにより連絡させて頂きます。

Allergen Challenge

Study Name: HZA113126 - A randomised, double blind, placebo-controlled, four-way crossover, repeat dose study comparing the effect of inhaled fluticasone furoate/GW642444M combination, GW642444M and fluticasone furoate on the allergen-induced asthmatic response in subjects with mild asthma.

Criteria: MILD asthmatic, INTERMITTENT use of ventolin or bricanyl permitted. Regular use of inhaled steroids (seretide) not permitted. 18-64 yrs of age. Female subjects permitted only if surgically sterile or post menopausal.

Patient Studies

Multiple Sclerosis

Study Name: NGM112988 - A randomized, double-blind, placebo-controlled, single ascending dose study exploring the preliminary safety, tolerability & pharmakokinetics of GSK1223249 administered by intravenous infusion to patients with relapsing forms of multiple sclerosis. not on disease modifying therapy.

Anti-cancer

Study Name: PKB112835 - A Phase I, Open-Label, Two-Stage study to investigate the safety, tolerability, Pharmakokinetcs and Pharmacodynamics of the oral AKT Inhibitor GSK2110183 in subjects with any hematologic malignancy.

Criteria: Diagnosed hematologic malignancy (incl. CLL, CML, MM, NHL or Hodgkin's lymphoma), at least 18 yrs of age.

(Letter of Interest / Study Calendars where available, in downloads section below)

♦Clinical trial volunteers are required to stay at the unit on several occasions throughout the course of the trial♦

To register your interest please call 1800 475 475 or email: volunteers.4.trials@gsk.com

Other Australian Sites

Non-Small Cell Lung Cancer

Study Name: 109493 (MAGRIT) - A Phase III study to assess the effectiveness of recMAGE-A3 +AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3 positive Non-Small Cell Lung Cancer.
More information

Chronic Obstructive Pulmonary Disease (COPD)

Study Name: HZC102871 (ANCHOR) and HZC102970 (CLIPPER) - A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD).

Notes of Interest:

Over 3000 patients worldwide will be invited to take part in these studies.
The study drug requires once a day usage, hence it may improve regular use of medicine.
Volunteers will be required to see their study doctor roughly once a month (sometimes every 2 months) for up to a year. The visits involve simple breathing checks and some tests. Volunteers will be treated at no cost to them.

YOU may be eligible if: